Title: Abstracts of the 26th European Workshop on Neonatology, September 2–5, 2018, Cappadocia, Turkey
Abstract: Introduction: It remains controversial whether transient hypothyroxinemia of prematurity infl uences short-and long-term outcomes.Thus, we aimed to defi ne a thyroxin threshold associated with neonatal clinical impairment and outcome at 3 years of age.Methods: We retrospectively analyzed medical records of infants born at a gestational age (GA) of < 29 weeks.A thyroxin threshold value was defi ned by ROC curve analysis in a cohort of infants born from 10/2008-12/2012, and validated in a second cohort of infants born from 01/2014-12/2016 in our institution.Results: Our analysis included 460 patients (mean GA, 26.7 ± 1.3 weeks; mean birth weight, 935 ± 206 g).Thyroxin (FT4) measurements were available for 196/274 infants from the early time period, among whom 35 exhibited neonatal clinical impairment.ROC curve analysis indicated an FT4 threshold of 10 pmol/L, with a sensitivity of 85.7%, and a specifi city of 49.1%.FT4 measurements were available for 176/186 infants from the second time period: neonatal clinical impairment occurred in 20/78 infants with FT4 ≤ 10 pmol/L versus 3/98 with FT4 > 10 pmol/L (P <.001).Three-year follow-up data were available for 147/196 eligible infants.Poor outcome occurred in 65% (58/89) with FT4 ≤ 10 pmol/L versus 34% (20/58) with FT4 > 10 pmol/L (OR, 3.555; 95% CI, 1.774-7.128;P <.001). Conclusion:We defi ned and validated a FT4 threshold of 10 pmol/L as a signifi cant risk factor for neonatal clinical impairment, and a good predictor of poor outcome at 3 years of age.